â??A STUDY TO DECIDE DOSE OF ITRACONAZOLE(ANTIFUNGAL DRUG)IN THE TREATMENT OF FUNGAL BALL IN TREATED PATIENTS OF TUBERCULOSISâ??

â??A COMPARATIVE STUDY OF ITRACONAZOLE IN VARIOUS DOSE SCHEDULES IN TREATMENT OF PULMONARY ASPERGILLOMA IN TREATED PATIENTS OF PULMONARY TUBERCULOSISâ??

Status

Active, not recruiting

Phases

Phase 3Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2013/02/003374

Enrollment

Registered

2013-02-11

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Old Treated Pulmonary TB Patients Now Diagnosed as Aspergilloma.

Interventions

Intervention1: Itraconezole: Oral, daily, 200mg, 6 months Control Intervention1: Itraconezole: 1. Oral, daily, 400mg for 6 months 2.Oral, daily, variable dose for 6 months as per body weight

Eligibility

Inclusion criteria

Inclusion criteria: Treated cases of Pulmonary TB now Diagnosed as Aspergilloma

Exclusion criteria

Exclusion criteria: Patient suffering from other medical diseases.

Design outcomes

Primary

Measure	Time frame
Clinical improvement. Radiological improvement. Serological improvement(Decline of serum titres) Timepoint: Clinical, Radiological & Serological (Decline of serum titres)at 2,6 & 12 months	—

Secondary

Measure	Time frame
Side effectsTimepoint: 3,6,12 mths	—

Countries

India

Contacts

Public ContactDr P R Gupta

SMS Medical College, Jaipur

guptapr_dr@hotmail.com9414071748

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026